Search This Blog

Monday, January 31, 2022

Reata Starts FDA Rolling Submission for Friedreich’s Ataxia Med

 Reata Pharmaceuticals, Inc. (Nasdaq: RETA), ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, today announced that the company has initiated a rolling submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for omaveloxolone for the treatment of patients with Friedreich’s ataxia. The rolling submission allows Reata to submit portions of the regulatory application to the FDA for review on an ongoing basis. The company reiterates that it expects to complete the submission of the NDA by the end of the first quarter of 2022.

https://finance.yahoo.com/news/reata-pharmaceuticals-initiates-rolling-submission-114500457.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.